Forty percent of hormone-receptor positive breast cancer patients are unresponsive to standard hormone/endocrine therapy, but recent research has shown anti-androgen therapies are a promising alternative, according to the release.
“The objective of our project is to design a therapeutic strategy to effectively target this hyperactive modified AR and prevent metastatic progression of ET-insensitive HR-positive breast cancer,” said Dr. Bawa-Khalfe.
“Working with collaborators in the UH College of Pharmacy and Lester and Sue Smith Breast Cancer Center at Baylor College of Medicine, we have identified actionable/druggable targets and corresponding molecular pathways that support accumulation of the active AR,” Dr. Bawa-Khalfe said. “We expect to generate novel therapeutics and evaluate clinically relevant compounds to inhibit these targets and in turn prevent metastatic progression of advanced ET-resistant breast cancer.”
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
